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Prediction of outcome in newly diagnosed myeloma: a
meta-analysis of the molecular proﬁles of 1905 trial patients
V Shah1, AL Sherborne1, BA Walker2, DC Johnson1, EM Boyle3, S Ellis1, DB Begum1, PZ Proszek1, JR Jones1, C Pawlyn1, S Savola4,
MW Jenner5, MT Drayson6, RG Owen7, RS Houlston1, DA Cairns8, WM Gregory8, G Cook9, FE Davies2, GH Jackson10, GJ Morgan2 and
MF Kaiser1 on behalf of the NCRI Haemato-oncology CSG
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required
as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations
in 1036 patients from the NCRI Myeloma XI trial and linked these to overall survival (OS) and progression-free survival.
Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients
(NDMM), we conﬁrm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard
ratios (HRs) for OS of 1.60 (P= 4.77 × 10− 7), 1.74 (P= 0.0005), 1.90 (P= 0.0089), 2.10 (P= 8.86 × 10− 14) and 1.68 (P= 2.18 × 10− 14),
respectively. Patients with ‘double-hit’ deﬁned by co-occurrence of at least two adverse lesions have an especially poor
prognosis with HRs for OS of 2.67 (P= 8.13 × 10− 27) for all patients and 3.19 (P= 1.23 × 10− 18) for intensively treated patients.
Using comprehensive CNA and translocation proﬁling in Myeloma XI we also demonstrate a strong association between
t(4;14) and BIRC2/BIRC3 deletion (P= 8.7 × 10− 15), including homozygous deletion. Finally, we deﬁne distinct sub-groups of
hyperdiploid MM, with either gain(1q21) and CCND2 overexpression (Po0.0001) or gain(11q25) and CCND1 overexpression
(Po0.0001). Proﬁling multiple genetic lesions can identify MM patients likely to relapse early allowing stratiﬁcation
of treatment.
Leukemia advance online publication, 30 June 2017; doi:10.1038/leu.2017.179
INTRODUCTION
While survival for multiple myeloma (MM) has improved over the
last decade with the introduction of immunomodulatory drugs
and proteasome inhibitors most MM patients will still relapse.1
Upfront identiﬁcation of patients who are likely to relapse early
offers the prospect of intervening pre-emptively to maintain
remission. Furthermore, identifying tumor sub-groups with
targetable molecular dependencies has the potential to inform
on biologically driven therapy.
Myeloma cells are typiﬁed by recurrent chromosomal aberra-
tions, a number of which have been variously associated with
poor prognosis, notably t(4;14), t(14;16), t(14;20), deletion 17p and
gain of 1q.2 We and others have recently reported that the co-
occurrence of multiple genetic lesions may have greater
signiﬁcance for predicting patient outcome than any single
abnormality.3,4 Since many of the molecular abnormalities in
MM are only present at relatively low frequency, robustly
establishing the impact of molecular sub-classes on prognosis is
contingent on the analysis of large patient series that have been
uniformly treated.
Here we report a meta-analysis of the relationship between
genetic proﬁle and prognosis in newly diagnosed MM (NDMM)
using data from two UK multi-center phase III clinical trials,
totalling 1905 patients. This dataset includes previously generated
data on the MRC Myeloma IX trial and an expanded analysis of the
NCRI Myeloma XI trial. In addition, we analysed molecular copy
number proﬁling in 1036 Myeloma XI patients to identify sub-
groups with molecular addictions that could be therapeutically
targetable.5,6
MATERIALS AND METHODS
Myeloma XI trial patients
1036 patients with NDMM enrolled in the UK NCRI Myeloma XI phase III
trial were molecularly proﬁled. Trial characteristics are described in
Supplementary Methods. At the time of analysis, the trial endpoints have
not been published. Median follow-up was 36.0 months. The study was
undertaken with written informed consent from patients and ethical
approval was obtained from the Oxfordshire Research Ethics Committee
(MREC 17/09/09, ISRCTN49407852).
Myeloma IX trial patients
Detailed characteristics and main outcomes of MRC Myeloma IX have been
reported previously and summarised in Supplementary Methods.7 The
study was undertaken with written informed consent from patients and
ethical approval was obtained from the MRC Leukaemia Data Monitoring
and Ethics committee (MREC 02/08/95, ISRCTN68454111). For the present
analysis we included data from 869 of the 1960 NDMM patients with
available clinical and comprehensive cytogenetic data.3 Median follow-up
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for this group was 72 months.3,8 Accompanying gene expression and
mapping array data have been previously published (GSE15695).6,9,10
Samples
For both trials myeloma cells from bone marrow aspirate samples were
obtained at diagnosis and puriﬁed (495%) using immune-magnetic cell
sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). RNA and DNA were
extracted using RNA/DNA mini kit or Allprep kits (QIAGEN) according to
manufacturers’ instructions.
Copy number and translocation detection
Technical details about ﬂuorescence in situ proﬁling of Myeloma IX have
been published previously.11 Myeloma XI cases were centrally analysed
using MLPA and qRT-PCR. The SALSA MLPA P425-B1 MM probemix (MRC
Holland, Amsterdam, The Netherlands) was used as previously
described.12,13 The newly developed probemix X073-A1 was used to
proﬁle 1007 of the 1036 cases in an identical fashion (MLPA Probe Mix:
Supplementary Table 1). Copy number at each locus was determined as
described previously.12,13
Multiplexed qRT-PCR was used to determine IGH translocation status
using a translocation and cyclin D (TC)-classiﬁcation based algorithm
(Supplementary Methods), as previously described.10
Statistical methods
All statistical analyses were undertaken using R version 3.3 and the
‘survival’, ‘rms’, ‘metafor’, ‘survC1’, ‘JAGS’ and ‘BayesMed’ packages.14
Progression-free survival (PFS) was deﬁned as the time from the date of
randomization to progression, according to IMWG criteria, or death from
any cause. Overall survival (OS) was deﬁned as the time from the date of
randomization to death from any cause. Kaplan–Meier survival curves were
generated and the homogeneity between groups was evaluated with the
log-rank test. Cox regression analysis was used to estimate hazard ratios
(HRs) and respective 95% conﬁdence intervals (CI) and adjustment for
variables was performed by multivariable analysis. Fixed effects meta-
analysis was performed using individual patient data. Correlations between
structural aberrations were analysed using Bayesian inference. A Bayes
Table 1. Clinical characteristics and frequency of genetic aberrations in myeloma IX and myeloma XI trial patients
Myeloma IX trial Myeloma XI trial P-value
(Total n= 869) Missing information (Total n=1036) Missing information
Clinical characteristics
Female 339 (39.0%) 398 (38.4%) 0.81
Male 530 (61.0%) 638 (61.6%) 0.81
Intensive treatment pathway 511 (58.8%) 598 (57.5%) 0.64
Non-intensive treatment pathway 358 (41.2%) 438 (42.3%) 0.64
ISS I 130 (20.7%) 240 225 (23.1%) 61 0.27
ISS II 253 (40.2%) 240 429 (44.0%) 61 0.15
ISS III 246 (39.1%) 240 321 (32.9%) 61 0.01
Median age (years) 65 (range 34–89) 67 (range 34–88) 1.0
Primary lesions (translocations, HRD)
t(4;14) 104 (11.9%) 137 (13.2%) 0.45
t(4;14) FGFR3-negative – 26 (2.5%)
t(6;14) 8 (0.9%) 1 7 (0.7%) 0.61
t(11;14) 129 (14.8%) 175 (16.9%) 0.23
t(14;16) 27 (3.1%) 38 (3.7%) 0.53
t(14;20) 13 (1.5%) 13 (1.3%) 0.69
HRD 499 (58.9%) 22 488 (47.1%) 3 × 10− 7
Copy number abnormalities
Del(1p32) 87 (10.7%) 60 107 (10.3%) 0.82
Gain(1q) or Amp(1q) 340 (39.1%) 357 (34.5%) 0.04
Gain(1q) – 277(26.7%)
Amp(1q) – 80 (7.7%)
Gain(6p) or Amp(6p) – 122 (12.1%) 29
Gain(6q) or Amp(6q) – 69 (6.9%) 29
Del(6q) – 157 (15.6%) 29
Del(8p) – 164 (16.3%) 29
Gain(8q) – 43 (4.3%) 29
Gain(11q25) – 418 (41.5%) 29
Del(12p) – 78 (7.5%)
Del(13q) 389 (45.1%) 6 425 (41.0%) 0.07
Del(14q) – 144 (13.9%)
Del(16q) 153 (17.6%) 46 175 (16.9%) 0.36
Del(17p) 78 (8.9%) 96 (9.3%) 0.87
Del(22q) 100 (13.1%) 103 103 (10.2%) 29 0.04
Focal copy number abnormalities/mutations
CDKN2C homozygous del – 19 (1.8%)
BIRC2/BIRC3 homozygous del – 22 (2.2%) 29
MYC ampliﬁcation – 28 (2.8%) 29
CCND1 focal gain – 46 (4.6%) 29
BRAF V600E mutation – 36 (3.6%) 29
Abbreviations: HRD, hyperdiploid; ISS, International Staging System.
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factor (BF01) of BF01o0.01 was considered signiﬁcant. The association
between categorical variables was examined using the Fisher exact test.
The association between myeloma subtype and gene expression was
assessed using the Mann–Whitney test. A two-sided P-value o0.05 was
considered signiﬁcant.
RESULTS
Descriptive patient characteristics and structural aberrations
The clinical characteristics of the 1036 newly proﬁled Myeloma XI
trial patients and the 869 Myeloma Trial IX patients are detailed in
Table 1. Overall there were no signiﬁcant differences between trial
patients in terms of gender, age and proportion that had been in
receipt of intensive/non-intensive therapy. Although the frequen-
cies of the primary IGH translocations, del(17p), del(1p32), del(13q)
and del(16q) in tumours were similar in Myeloma IX and XI trial
patients, a higher proportion of Myeloma IX patients had
hyperdiploidy (HRD), gain(1q) and del(22q) (Table 1). Amongst
Myeloma XI trial patients, homozygous deletion of CDKN2C (1p32),
BIRC2/BIRC3 (11q22) and ampliﬁcation of CKS1B (1q21) and MYC
(8q24) were the commonest focal homozygous copy number
changes, which were seen at similar frequencies to those
previously reported (Table 1).15
Relationship between cytogenetic aberrations and survival
In both trial series, the archetypical high-risk lesions del(17p), gain
(1q) and t(4;14) were each signiﬁcantly associated with shorter PFS
and OS (Table 2). In the combined analysis, respective HR for OS
were 2.1 for del(17p) (P= 8.86 × 10− 14), 1.68 for gain(1q)
(P= 2.18 × 10− 14) and 1.60 for t(4;14) (P= 4.77 × 10− 7; Table 2;
Supplementary Figures 1 and 2). In addition, the t(14;16) and t
(14;20) translocations involving MAF and MAFB were also
associated with shorter OS with respective HRs of 1.74
(P= 0.0005) and HR 1.90 (P= 0.0089). Respective inference
C-statistic estimates for adequacy of risk prediction are shown in
Supplementary Tables 5 and 6.
Deletion of 1p32 (CDKN2C) was signiﬁcantly associated with
shorter OS (HR 1.46; P= 0.0002; Table 2). This association was
conﬁned to patients in receipt of intensive treatment (in the
combined analysis: HR 1.89; P= 1.23 × 10− 5 vs HR 1.05; P= 0.72 for
non-intensive treatment). The association of del(1p32) with OS
was independent from gain(1q21) by multivariable analysis
(Po0.05) in the intensive treatment groups of both trials.
To examine the relationship between 1q21 status and outcome
in more detail we sub-classiﬁed Myeloma XI patients (n= 1036) by
diploid vs gain vs ampliﬁcation status. 1q21 gain was conﬁrmed as
a high-risk lesion and was associated with signiﬁcantly shorter PFS
(HR 1.56; P= 3.53 × 10− 7) and OS (HR 1.67; P= 3.30 × 10− 5) than
Table 2. Relationship between genetic abnormalities and patient survival
Myeloma IX
n= 869
Myeloma XI
n= 1036
Combined
n= 1905
Heterogeneity
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(a) Progression-free survival
t(4;14) 1.88 (1.52–2.23) 5.31 × 10− 9 1.51 (1.22–1.88) 0.0001 1.69 (1.45–1.96) 9.30 × 10− 12 0.16
t(14;16) 1.50 (1.01–2.22) 0.0425 1.51 (1.05–2.17) 0.0256 1.50 (1.15–1.96) 0.0026 0.98
t(14;20) 1.13 (0.64–1.99) 0.6852 1.54 (0.80–2.97) 0.1987 1.29 (0.84–1.98) 0.2509 0.48
Adverse translocations 1.77 (1.47–2.13) 1.88 × 10− 9 1.58 (1.31–1.91) 2.05× 10− 6 1.67 (1.46–1.91) 2.69 × 10− 14 0.41
Del(17p) 1.54 (1.21–1.95) 0.0003 1.61 (1.26–2.06) 0.0002 1.57 (1.33–1.87) 2.07× 10− 7 0.79
Gain(1q) 1.53 (1.33–1.77) 6.70 × 10− 9 1.53 (1.31–1.80) 1.34× 10− 7 1.53 (1.38–1.71) 4.61 × 10− 15 1.00
Del(1p32) 0.99 (0.78–1.25) 0.9202 1.30 (1.02–1.66) 0.0331 1.13 (0.95–1.34) 0.1571 0.11
ISS II 1.40 (1.12–1.76) 0.0036 1.54 (1.23–1.92) 0.0002 1.47 (1.25–1.72) 2.50× 10− 6 0.58
ISS III 1.64 (1.30–2.06) 2.34 × 10− 5 2.46 (1.96–3.09) 6.88 × 10− 16 2.02 (1.71–2.37) 1.73 × 10− 17 0.01
1 Adverse lesion 1.41 (1.21–1.65) 1.73 × 10− 5 1.46 (1.23–1.74) 1.44× 10− 5 1.44 (1.28–1.61) 1.07× 10− 9 0.76
‘Double hit’ 41 adverse lesion 2.24 (1.83–2.76) 1.11× 10− 14 2.22 (1.78–2.77) 1.05 × 10− 12 2.23 (1.92–2.59) 7.92 × 10− 26 0.94
Intermediate risk-ISS 1.50 (1.25–1.79) 1.48 × 10− 5 1.95 (1.63–2.33) 1.56 × 10− 13 1.71 (1.51–1.95) 9.48 × 10− 17 0.04
‘Double hit’-ISS 2.76 (2.13–3.57) 1.54× 10− 14 2.93 (2.29–3.09) 2 × 10− 16 2.85 (2.38–3.40) 8.32 × 10− 31 0.74
Myeloma IX
n = 869
Myeloma XI
n = 1036
Combined
n = 1905
Heterogeneity
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(b) OS
t(4;14) 1.72 (1.36–2.17) 5.12 × 10− 6 1.42 (1.06–1.91) 0.0188 1.60 (1.33–1.92) 4.77 × 10− 7 0.33
t(14;16) 1.52 (0.98–2.35) 0.0607 2.00 (1.28–3.11) 0.0021 1.74 (1.27–2.37) 0.0005 0.39
t(14;20) 1.64 (0.88–3.07) 0.1213 2.35 (1.11–4.97) 0.0259 1.90 (1.17–3.07) 0.0089 0.47
Adverse translocations 1.74 (1.42–2.14) 1.15 × 10− 7 1.71 (1.33–2.20) 3.23 × 10− 5 1.73 (1.47–2.03) 1.63× 10− 11 0.90
Del(17p) 1.92 (1.49–2.48) 6.07 × 10− 7 2.40 (1.77–3.24) 1.61 × 10− 8 2.10 (1.73–2.56) 8.86× 10− 14 0.27
Gain(1q) 1.61 (1.37–1.91) 1.81 × 10− 8 1.80 (1.44–2.24) 1.76 × 10− 7 1.68 (1.47–1.92) 2.18× 10− 14 0.44
Del(1p32) 1.23 (0.94–1.61) 0.1170 1.83 (1.35–2.48) 0.0001 1.46 (1.20–1.78) 0.0002 0.06
ISS II 1.98 (1.47–2.68) 8.11 × 10− 6 1.90 (1.30–2.77) 0.0009 1.95 (1.54–2.47) 2.76 × 10− 8 0.86
ISS III 2.62 (1.94–3.53) 2.69 × 10− 10 3.85 (2.66–5.56) 7.41 × 10− 14 3.05 (2.42–3.85) 4.38× 10− 21 0.11
1 Adverse lesion 1.42 (1.18–1.71) 0.0002 1.81 (1.41–2.32) 3.57 × 10− 6 1.55 (1.33–1.79) 9.97 × 10− 9 0.13
‘Double hit’ 41 Adverse lesion 2.54 (2.02–3.18) 7.77 × 10− 16 2.91 (2.17–3.89) 1.11 × 10− 12 2.67 (2.23–3.19) 8.13× 10− 27 0.47
Intermediate risk-ISS 1.96 (1.57–2.45) 4.26 × 10− 9 2.59 (1.96–3.41) 1.62 × 10− 11 2.19 (1.84–2.61) 1.3 × 10− 18 0.13
‘Double hit’-ISS 3.93 (2.93–5.27) 2 × 10− 16 4.37 (3.13–6.12) 2 × 10− 16 4.12 (3.30–5.14) 2.85× 10− 36 0.64
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; ISS, International Staging System; OS, overall survival.
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normal 1q copy number status. Amp(1q) was also associated with
shorter PFS (HR 1.44; P= 0.01) and OS (HR 2.28; P= 2.32 × 10− 6)
compared to normal 1q, but there was no signiﬁcant difference to
gain(1q) (PFS: HR 0.91; P= 0.54; OS: HR 1.36; P= 0.09 for OS).
Median PFS was 19.4 vs 21.8 vs 30.1 months (Po0.0001) and
24-months OS 63.8 vs 77.5 vs 83.5% (Po0.0001) for amp(1q),
gain(1q) and normal 1q, respectively (Figure 1; Supplementary
Table 7).
‘Double-hit’ as a high-risk classiﬁer
We next examined the impact of a ‘double-hit’ based on the co-
occurrence of at least any two of the following: (1) Adverse
translocations t(4;14), t(14;16), t(14;20); (2) gain(1q); (3) del(17p).3
For Myeloma XI the three risk groups, deﬁned by ‘double-hit’, 1 or
no adverse lesions, were associated with median PFS of 17.0, 24.2
and 31.1 months (log-rank P= 5.7 × 10− 13), with corresponding
median 24-months OS of 66.1, 76.6 and 86.4% (P= 4.4 × 10− 13).
These ﬁndings were consistent with Myeloma IX (Table 2). In the
combined analysis of all 1905 patients the HR for ‘double-hit’ was
2.23 for PFS (P= 7.92 × 10− 26) and 2.67 for OS (P= 8.13 × 10− 27;
Table 2; Supplementary Figures 1 and 2). Similarly to Myeloma IX,
the ‘triple-hit’ of an adverse translocation, Gain(1q) and del(17p)
was associated with a very short median OS of 19 months with a
HR of 6.23 (P= 1.31 × 10− 7) vs no adverse lesion (Supplementary
Figure 5).
In both Myeloma IX and XI trials the impact of a ‘double-hit’ on
patient outcome was independent of International Staging System
(ISS; Supplementary Table 3). Moreover, integration of ISS and
genetic risk deﬁned ‘double-hit’-ISS ultra high risk (ISS II or III and
‘double-hit’; 12.0%), intermediate risk (ISS I and ‘double-hit’; ISS II
and 1 adverse lesion; ISS III and no or 1 adverse lesion; 44.1%) and
favourable risk groups (ISS I and no or 1 adverse lesion; ISS II and
no adverse lesion; 43.9%). 'double hit'-ISS ultra high risk was
associated with HR 2.85 (P= 8.32 × 10− 31) for PFS and HR 4.12
(P= 2.85 × 10− 36) for OS in the meta-analysis (Table 2).
Genetic markers and survival in intensively treated patients
Since young and ﬁt patients are most likely to be considered for
intensiﬁed combination therapy, we subsequently focused on the
relationship between molecular proﬁle and survival of this sub-
group of Myeloma XI (n= 598) and Myeloma IX (n= 511) patients.
In these 1109 intensively treated patients, del(17p), gain(1q) and
t(4;14) were consistently associated with shorter PFS and OS;
combined HRs of 2.65 (3.04 × 10− 12), 1.77 (1.65 × 10− 8) and 1.87
(7.62 × 10− 7), respectively (Table 3; Supplementary Figures 3 and
4). In this group, t(14;16) was associated with shorter PFS (HR 1.80;
P= 0.0021) and OS (HR 1.82; P= 0.013). The t(14;20) was not
associated with adverse PFS or OS, but the lesion was only present
in eight Myeloma IX and ﬁve Myeloma XI cases (Table 3;
Supplementary Figures 3 and 4).
In Myeloma XI, the groups with a ‘double-hit’, 1 adverse or no
adverse lesion were associated with median PFS of 19.7, 30.9 and
44.8 months (log-rank P= 2.5 × 10− 13) and 24-months OS of 72.3,
86.2 and 92.2% (P= 1.6 × 10− 10; Supplementary Figure 3). By meta-
analysis, intensively treated patients with a ‘double-hit’ had a HR
for PFS of 2.61 (P= 1.07 × 10− 20) and HR for OS of 3.19
(P= 1.23 × 10− 18; Table 3). Survival time increased for all risk
groups of intensively treated patients in Myeloma XI compared to
Myeloma IX (median PFS: 14.4, 21.9 and 30.8 months; 24 month
OS: 63.9, 75.4 and 86.0%, respectively). Median PFS was 5.3 months
longer for ‘double-hit’ in Myeloma XI vs IX, but 14 months longer
for the group without any risk lesion.
On the basis of clinical and genetic information (Supplementary
Table 4) the ‘double-hit’-ISS ultra high-risk group comprising
12.5% of patients were associated with a HR of 3.11
(P= 1.59 × 10− 20) for PFS and HR 4.79 (P= 5.10 × 10− 23) for OS.
Associations of copy number changes with translocations and
targetable lesions
We next focused on genetic sub-groups of MM that could be
speciﬁcally targetable using copy number and translocation data
on the 1036 Myeloma XI patients. Figure 2 provides an overview of
correlations between CNA and translocations (Supplementary
Table 2). Of particular note was a relationship between NFκB-
pathway CNA and translocation groups.
Potentially targetable NFκB-pathway gene deletions are common
in myeloma
Deletions of NFκB-pathway modulating genes TNFAIP3, BIRC2/
BIRC3, TRAF3 or CYLD were identiﬁed in 16.6, 4.8, 13.9 and 16.9% of
Myeloma XI cases, respectively. Nearly half of all tumors (43.2%)
harbored an NFκB-pathway gene abnormality. Overall, a deletion
of more than one NFκB-pathway gene was detectable in 9.7% of
Figure 1. Chromosome 1q21 copy number status and outcome in
Myeloma XI. Kaplan–Meier curves and log-rank P-values for (a) PFS
(b) OS for normal vs gain vs ampliﬁcation of 1q21.
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tumors and in 42.4% of these cases involved deletions of both
TNFAIP3 and CYLD.
t(4;14) myeloma is associated with BIRC2/BIRC3 deletions
We identiﬁed BIRC NFκB-pathway deletions to be enriched in
t(4;14) MM (Figure 2). Speciﬁcally, 29/135 (21.5%) t(4;14) vs 20/852
(2.3%) non-t(4;14) (P= 8.7 × 10− 15) tumors were BIRC2/BIRC3
deleted. Intriguingly, homozygous BIRC2/BIRC3 deletions were
present in 15/135 (11%) of t(4;14) as compared to 7/872
non-t(4;14) tumors (0.8%; BF01 = 4.3 × 10
− 12; P= 1.0 × 10− 8;
Supplementary Table 2). Almost all t(4;14) tumors (28/29) with
any BIRC2/BIRC3 deletion expressed FGFR3, more than expected
(P= 0.015). Deletions of TRAF3 (14q32) seen in t(4;14) were
mutually exclusive of BIRC deletions (P= 0.016) and more than
expected FGFR3-negative: 20/29 (69%; P= 0.0001). In contrast,
deletions of CYLD were generally signiﬁcantly under-represented
in the t(4;14) group (6/137; 4.4%) as compared with non-t(4;14)
(169/899; 18.8%; BF = 0.007; P= 4.0 × 10− 6).
High-risk and hypodiploidy-associated lesions
The t(4;14) subgroup was signiﬁcantly associated with hypodi-
ploidy lesions (HYL) del(12p) (BF = 1.1 × 10− 4), del(13q)
(BF = 1.1 × 10− 25) and del(22q) (BF = 1.1 × 10− 7; Figure 2).16 Dele-
tion of 17p was also associated with deletions of 12p (BF = 0.0004),
13q (BF = 3.7 × 10− 6) and 22q (BF = 0.0076), but there was no
correlation between del(17p) and t(4;14). MM with t(4;14) was
associated with gain(1q) (BF = 3.0 × 10− 8), but not with del(1p32),
which was only signiﬁcantly correlated with del(8q) (BF = 0.0009)
and del(16q23) (BF = 0.0003). In contrast, t(11;14) and HRD cases,
the latter deﬁned by extra copies of any two of chromosomes 5, 9
or 15, were negatively associated with gain(1q) (BF = 1.6 × 10 − 3
and BF = 0.06, respectively). Collectively, HRD cases were nega-
tively associated with del(13q) (BF = 1.9 × 10− 21) and del(22q)
(BF = 0.0002).
Molecular sub-classiﬁcation of hyperdiploid myeloma
We noted heterogeneity within the HRD subgroup in terms of co-
occurrence of lesions. Although HRD as a whole group was
strongly correlated with gain(11q25) (BF = 1.2 × 10− 66), a subgroup
lacking gain(11q25) was characterised by gain(1q) (Figure 3;
Supplementary Figure 6).
Of the 488 HRD cases in Myeloma XI, 68% had gain(11q25) and
29% gain(1q). Both lesions co-occurred in 15% of HRD cases, less
than expected (BF = 0.0004). Accordingly, most HRD patients could
be classiﬁed as having gain(1q)-HRD, gain(11q25)-HRD or gain(1q)
+gain(11q25)-HRD (Figure 2a). Gain(1q)-HRD was associated with
overexpression of CCND2 and silenced CCND1 (Po0.0001). In
contrast, gain(11q25) was associated with CCND1 expression and
Table 3. Relationship between genetic abnormalities and patient survival for intensively treated patients
Myeloma IX
n = 511
Myeloma XI
n = 598
Combined
n = 1109
Heterogeneity
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(a) Progression-free survival
t(4;14) 1.96 (1.49–2.59) 1.80 × 10− 6 2.03 (1.56–2.64) 2.18 × 10− 7 2.00 (1.65–2.42) 1.85 × 10− 12 0.88
t(14;16) 1.60 (0.96–2.69) 0.0729 2.03 (1.19–3.47) 0.0099 1.80 (1.23–2.60) 0.0021 0.54
t(14;20) 0.96 (0.46–2.03) 0.9192 0.64 (0.09–4.54) 0.6524 0.91 (0.45–1.84) 0.7987 0.70
Adverse translocations 1.81 (1.42–2.31) 1.79 × 10− 6 2.09 (1.62–2.68) 8.88 × 10− 9 1.94 (1.63–2.31) 1.07 × 10− 13 0.42
Del(17p) 1.81 (1.30–2.51) 0.0004 1.81 (1.29–2.52) 0.0005 1.81 (1.43–2.28) 7.25× 10− 7 1.00
Gain(1q) 1.48 (1.22–1.80) 7.44 × 10− 5 1.65 (1.31–2.07) 2.03 × 10− 5 1.55 (1.34–1.80) 7.59× 10− 9 0.49
Del(1p32) 1.05 (0.76–1.47) 0.7556 1.48 (1.04–2.09) 0.0286 1.23 (0.97–1.57) 0.0833 0.17
ISS II 1.34 (1.01–1.77) 0.0409 1.48 (1.11–1.99) 0.0085 1.40 (1.15–1.72) 0.0009 0.61
ISS III 1.43 (1.07–1.91) 0.0168 2.20 (1.61–3.01) 7.88 × 10− 7 1.74 (1.40–2.16) 3.11× 10− 7 0.04
1 Adverse lesion 1.50 (1.21–1.85) 0.0002 1.49 (1.15–1.93) 0.0024 1.50 (1.27–1.76) 1.36× 10− 6 0.99
‘Double hit’ 41 adverse lesion 2.31 (1.75–3.05) 3.67× 10− 14 3.00 (2.24–4.02) 2.17 × 10− 13 2.61 (2.13–3.20) 1.07 × 10− 20 0.21
Intermediate risk-ISS 1.47 (1.16–1.86) 0.0015 1.87 (1.45–2.41) 1.45 × 10− 6 1.64 (1.38–1.95) 2.10× 10− 8 0.17
‘Double hit’-ISS 2.78 (1.96–3.95) 9.85 × 10− 9 3.42 (2.47–4.75) 1.92 × 10− 13 3.11 (2.45–3.95) 1.59 × 10− 20 0.40
Myeloma IX
n = 511
Myeloma XI
n = 598
Combined
n = 1109
Heterogeneity
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(b) OS
t(4;14) 1.74 (1.26–2.41) 0.0008 2.09 (1.41–3.07) 0.0002 1.87 (1.46–2.40) 7.62× 10− 7 0.49
t(14;16) 1.51 (0.79–2.84) 0.2059 2.31 (1.13–4.73) 0.0218 1.82 (1.13–2.92) 0.01359 0.38
t(14;20) 1.44 (0.59–3.49) 0.4181 1.91 (0.26–13.70) 0.5219 1.51 (0.67–3.39) 0.3169 0.80
Adverse translocations 1.74 (1.30–2.33) 0.0002 2.30 (1.60–3.31) 6.99× 10− 6 1.94 (1.55–2.43) 9.91× 10− 9 0.24
Del(17p) 2.31 (1.61–3.31) 5.87 × 10− 6 3.19 (2.10–4.85) 5.74× 10− 8 2.65 (2.01–3.48) 3.04 × 10− 12 0.25
Gain(1q) 1.79 (1.40–2.27) 2.33 × 10− 6 1.72 (1.22–2.43) 0.0020 1.77 (1.45–2.15) 1.65× 10− 8 0.86
Del(1p32) 1.84 (1.28–2.64) 0.0010 1.99 (1.25–3.18) 0.0037 1.89 (1.42–2.52) 1.23× 10− 5 0.78
ISS II 1.96 (1.32–2.90) 0.0008 1.88 (1.14–3.11) 0.0140 1.92 (1.41–2.63) 3.27× 10− 5 0.90
ISS III 2.56 (1.72–3.81) 3.59 × 10− 6 3.22 (1.94–5.35) 6.56× 10− 6 2.79 (2.04–3.81) 1.30 × 10− 10 0.49
1 Adverse lesion 1.73 (1.32–2.26) 6.91 × 10− 5 1.62 (1.08–2.44) 0.0207 1.69 (1.35–2.12) 4.30× 10− 6 0.79
‘Double hit’ 41 Adverse lesion 2.84 (2.05–3.94) 3.70 × 10− 10 3.88 (2.55–5.92) 2.98 × 10− 10 3.19 (2.47–4.14) 1.23 × 10− 18 0.25
Intermediate risk-ISS 2.36 (1.71–3.25) 1.44 × 10− 7 2.26 (1.49–3.43) 0.0001 2.32 (1.80–3.00) 7.15 × 10− 11 0.87
‘Double hit’-ISS 4.51 (2.97–6.83) 1.26 × 10− 12 5.18 (3.24–8.27) 5.78 × 10− 12 4.79 (3.51–6.54) 5.10 × 10− 23 0.66
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; ISS, International Staging System; OS, overall survival.
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silenced CCND2 (Po0.0001). We validated this correlation
between gain(1q)-HRD and CCND2 and gain(11q25)-HRD and
CCND1 expression in the Myeloma IX dataset (Supplementary
Figure 7). The TC classiﬁcation-deﬁned D1 and D2 sub-groups of
HRD MM on the basis of CCND1 and CCND2 overexpression17 and
our ﬁndings suggest similarity between gain(11q25)-HRD and the
D1, gain(1q)-HRD and the D2 and gain(1q)+gain(11q)-HRD and the
D1+D2 TC classiﬁcation subgroup.
Further differences between the HRD subtypes were noted: 13q
was deleted in 41.1% (58/141) of gain(1q)-HRD (BF = 6.0 × 10− 6;
Po0.0001), but only in 15.4% (50/325) of gain(11q25)-HRD
(BF = 5.5 × 10− 11; Po0.0001). We validated this ﬁnding in the
Myeloma IX dataset, where del(13q) was also positively associated
with gain(1q)-HRD (P= 0.024) and negatively associated with gain
(11q25) (P= 0.041).
Prognostic impact of molecular sub-groups in HRD
Gain of 1q, del(1p32) and del(17p) was associated with shorter OS
(HR 1.81, P= 0.001; HR 2.44, P= 0.0004; HR 1.89, P= 0.022;
respectively) in the 488 HRD cases. Gain(1q) and del(1p32) but
not del(17p) was also associated with shorter PFS (HR 1.56,
P= 0.0003; HR 1.66, P= 0.005; HR 1.30, P= 0.23 respectively;
(Supplementary Table 8, Supplementary Figure 8)). Gain of
11q25, del(13q) and del(22q) were not associated with shorter
OS or PFS. At least one of the lesions gain(1q), del(1p32) or del
(17p) were present in 39.3% (192/488) of HRD cases, deﬁning a risk
population with signiﬁcantly shorter PFS (P= 4.9 × 10− 6) and OS
(P= 2.7 × 10− 6; Supplementary Figure 9) compared to HRD MM
lacking any of these lesions. Interestingly, the 28.5% of all patients
(296/1036) that had HRD without any demonstrable adverse
lesion, had the longest survival of all sub-groups, indeed longer
than those with t(11;14) MM (Figure 4).
DISCUSSION
Our analysis conﬁrms the association with outcome in MM for the
archetypical high-risk lesions del(17p), gain(1q) and adverse
translocations and emphasises the importance of ‘double-hit’ as
a risk biomarker. Importantly, we demonstrate that this informa-
tion can be combined with the ISS to further reﬁne risk
prediction.3,18–21 To our knowledge, this study represents the
largest analysis investigating the additive effect of multiple
genetic lesions on outcome in NDMM. Importantly, our analysis
has been based on trials that recruited between 2003 and 2016, a
timeframe during which treatment for MM has undergone
signiﬁcant change.22 The consistent adverse impact of high-risk
genetics on survival in Myeloma IX and XI is striking and highlights
the need for intensiﬁed efforts to target the biology of high-risk
disease. Although survival time increased for all risk groups in
Myeloma XI vs IX, absolute improvement was smallest for the
‘double-hit’ high-risk group. Median PFS for ‘double-hit’ in
Myeloma XI patients receiving intensive treatment was
19.7 months, meaning that about half of patients relapsed
12 months following autologous transplant.
Comprehensive assessment of the inter-relationship of CNAs
and translocations in the Myeloma XI trial led to characterisation
of genetic sub-groups with putative therapeutic relevance. We
found that half of Myeloma XI tumors carried a deletion of NFκB-
pathway genes, and 10% of tumors had two co-occuring
deletions.23–25 Intriguingly, our data suggests NFκB-inducing
kinase (NIK)-speciﬁc addiction of the t(4;14) group: BIRC2/BIRC3
deletions, including homozygous deletions, were enriched in
t(4;14) tumours. The t(4;14) MM without BIRC2/BIRC3 deletions
were frequently TRAF3 deleted. BIRC2, BIRC3 and TRAF3 proteins
all interact directly with NIK, suppressing NFκB-pathway activity.
(25) MM cell lines with deletions of BIRC2/BIRC3 or TRAF3,
predominantly t(4;14), have high NIK levels and activated NFκB-
pathway signalling, as demonstrated by Keats et al. Recently,
speciﬁc NIK inhibitors have been developed which might be used
to target high-risk t(4;14) MM.26–28 Virtually all BIRC2/3 deletions
were found in FGFR3-positive tumors. They were mutually
exclusive of TRAF3 deletions, which were present in FGFR3-
negative tumors, a pattern which may indicate convergent
evolution. Deletions of FGFR3, which often occur as loss of der14
that includes TRAF3, may constitute ‘collateral damage’ of NIK
addiction in t(4;14).15,24,25,29,30
Although t(4;14) and del(17p) were not correlated with each
other, both groups were strongly associated with hypodiploidy-
associated lesions del(12p), del(13q) and del(22q).16,17,31,32 This
suggests the consequences of t(4;14) and del(17p) may share
molecular mechanisms. Gain of chromosome 1q21 was strongly
associated with t(4;14), but not with del(17p). Gain(1q21) was
conﬁrmed as a high-risk lesion that is independent of del
(1p32).33–35
HRD MM constitutes the largest genetic sub-group of patients,
with substantial heterogeneity.17 We describe two sub-groups of
HRD with either gain(11q25) and CCND1 biology or gain(1q21)
and CCND2 overexpression. These groups are similar to the D1 and
D2 sub-groups of the TC classiﬁcation, which pioneered biologic
classiﬁcation of HRD MM. Application of the TC classiﬁcation in
routine diagnostics has unfortunately been restricted due to
access limitations to array-based gene expression proﬁling.17
Pragmatic classiﬁcation of HRD based on gain(11q25) and gain(1q)
may facilitate sub-grouping in clinical practice and open
opportunities for improving therapy for these patients. Recently,
activity of bcl-2 inhibitors has been reported in CCND1-driven
t(11;14) MM, and CCND1-driven gain(11q25)-HRD may constitute
another target group.36 We also found a high frequency of del
(13q) in gain(1q)-HRD, in contrast to gain(11q25)-HRD. Interest-
ingly, del(13q) and gain(1q) also frequently co-occur in t(4;14),
suggesting similarities in the genetic sequelae of these pathoge-
netic groups.37 An inter-relationship between del(13q) and gain
(1q)-HRD was suggested based on GEP in the TC classiﬁcation by
Bergsagel et al., but has been demonstrated here for the ﬁrst time
on a DNA level.17,38 Moreover, HRD MM without any of risk lesions
Figure 2. Associations between copy number aberrations and translo-
cations in Myeloma XI. A Bayesian approach was used to identify all
potential associations between genetic lesions. Signiﬁcant interactions
(BFo0.01) are colour-coded, red representing positive and blue
negative associations. Correlation factors and Bayes Factors are
provided in Supplementary Table 2. amp, ampliﬁcation; foc gain, focal
gain; hmz del, homozygous deletion.
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Figure 3. HRD genetic sub-groups in Myeloma XI. (a) Each row represents one of in total 1007 cases. Expression intensity is coded in green for
CCND1 and red for CCND2 expression. Gain of 11q25 is shown in dark green, gain of 1q in dark red and deletion 13q in dark blue; white=no
abnormality detected. B+C. CCND1 (b) and CCND2 (c) qRT-PCR expression levels (relative quantitative RQ values, GAPDH normalised) for HRD
cases with gain(1q), gain(1q)+gain(11q25), gain(11q25) or neither. Gene expression levels were signiﬁcantly different for all possible group-
wise comparisons (two-sided Mann–Whitney U test; ****Po0.0001; ***Po0.001).
Figure 4. Survival in HRD MM with and without risk factors in Myeloma XI. Kaplan–Meier curves and log-rank P-values for (a) PFS (b) OS.
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gain(1q)-HRD, del(17p) and del(1p32) had longer remissions
and survival than any other sub-group and may be sufﬁciently
treated with single-novel agent/immunomodulatory drug-based
approaches, potentially reducing additional side effects and costs
of novel agent combinations.39–42
In summary, we demonstrate the utility of proﬁling multiple
molecular genetic lesions to identify patients most likely to beneﬁt
from molecularly targeted therapies. The molecular tools used for
proﬁling Myeloma XI are readily applicable within diagnostic
settings and should therefore help implementing stratiﬁed
treatment approaches as part of routine patient care.
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